|Expense Ratio (net)||0.77%|
|Morningstar Risk Rating||★★★|
|Last Cap Gain||0.00|
|Inception Date||Dec 29, 1995|
|Average for Category||N/A|
Biotech stocks have taken off since President Trump took office. Through the end of July, the iShares Biotech ETF is up almost 19%, well ahead of broader market benchmarks. If you are thinking of investing in biotech stocks after this rally, here's what you need to know.
Ziad Bakri, manager of the T. Rowe Price Health Sciences Fund, looks for three main themes in his stock picks.
The healthcare sector is strong this year, despite earlier uncertainty over the ACA. Check out these top mutual funds if you're ready to invest.